This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma
Journal of Experimental & Clinical Cancer Research Open Access 02 December 2021
-
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Clinical Epigenetics Open Access 29 May 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Minucci S, Pelicci PG . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38–51.
Dyson MH, Thomson S, Inagaki M, Goto H, Arthur SJ, Nightingale K et al. MAP kinase-mediated phosphorylation of distinct pools of histone H3 at S10 or S28 via mitogen- and stress-activated kinase 1/2. J Cell Sci 2005; 118: 2247–2259.
Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP . Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 2005; 33: 53–61.
Nishioka C, Ikezoe T, Takeshita A, Yang J, Tasaka T, Yang Y et al. ZD6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel MEK inhibitor, AZD6244. Leukemia 2007; 21: 1308–1310.
Prigent C, Dimitrov S . Phosphorylation of serine 10 in histone H3, what for? J Cell Sci 2003; 116: 3677–3685.
Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S et al. Phase 1 and pharmacological study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007; 109: 2781–2790.
Acknowledgements
This work was supported in part by grant-in-aid from the Ministry of Education, Culture Sports, Science, and Technology of Japan; Kanae Foundation for the Promotion of Medical Science; Public Trust of Haraguchi Memorial Cancer Research Fund and the Fund for Academic Research from Kochi University. HPK is supported by NIH grants, as well as the Inger Fund and the Parker Hughes Trust.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Rights and permissions
About this article
Cite this article
Nishioka, C., Ikezoe, T., Yang, J. et al. Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell. Leukemia 22, 1449–1452 (2008). https://doi.org/10.1038/sj.leu.2405079
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2405079
This article is cited by
-
Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma
Journal of Experimental & Clinical Cancer Research (2021)
-
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Clinical Epigenetics (2019)
-
Integrated Drug Expression Analysis for leukemia: an integrated in silico and in vivo approach to drug discovery
The Pharmacogenomics Journal (2017)
-
Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells
Annals of Hematology (2011)
-
Different effect of protein kinase B/Akt and extracellular signal-regulated kinase inhibition on trichostatin A-induced apoptosis in epithelial ovarian carcinoma cell lines
Molecular and Cellular Biochemistry (2011)